Poxel SA and Sumitomo Pharma: A Closer Look at TWYMEEG®’s Sales Performance and Strategic Growth Initiatives In the rapidly evolving landscape of metabolic disease treatments, Poxel SA (Euronext: POXEL – FR0012432516) stands out as a pioneering clinical-stage biopharmaceutical company. With…
New Study Shows DCT Components Boost Diversity, But Gaps Remain for Black Participants DCT Components, The lack of diversity in clinical trials has been a persistent issue, with racial, ethnic, and gender disparities often leaving underrepresented communities excluded from critical…
ImmunityBio, Inc. (NASDAQ: IBRX) has announced a strategic collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company. The partnership will focus on conducting a confirmatory, randomized Phase 3 clinical trial (ResQ201A-NSCLC),…
Arizona ADHD Center Expands with New Scottsdale Clinic, Enhancing ADHD Diagnosis and Treatment Arizona ADHD Center, a premier medical and behavioral health clinic specializing in ADHD diagnosis, treatment, and ongoing management, is proud to announce the opening of its new…
Roche Receives FDA Clearance for CLIA-Waived STI Point-of-Care Tests Roche has announced a major milestone in the realm of sexual health diagnostics. The U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance and Clinical Laboratory Improvement Amendments…
Eli Lilly and Company has announced that the U.S. FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults. This approval marks a significant milestone for the company, as Omvoh is now approved…
Incyte and Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The companies expect the product to be available for order in the United States by early…
Datopotamab Deruxtecan Granted Priority Review by FDA for Advanced EGFR-Mutated NSCLC AstraZeneca and Daiichi Sankyo recently announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd). This development marks a…
Introduction to Heart Failure and the Need for New Treatments Bayer has announced that it has submitted marketing authorization applications to both the U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE), seeking approval for finerenone…
Biologics License Grifols Advances Fibrinogen Solution with U.S. FDA Submission Biologics License Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, has announced the submission of a Biologics License Application (BLA) for its innovative fibrinogen treatment to the…
GSK Receives FDA Breakthrough Therapy Designation for GSK5764227 in Osteosarcoma Treatment GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK’227), its targeted antibody-drug conjugate (ADC) designed to treat…
The oncology pharmaceuticals market, valued at $196.4 billion in 2023, is expected to grow at a robust compound annual growth rate (CAGR) of 12.7%, reaching $401.4 billion by 2029. This remarkable growth is driven by several factors, including increasing cancer…